Wolff Financial Management LLC Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Wolff Financial Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 23.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 45,054 shares of the biopharmaceutical company’s stock after selling 14,012 shares during the quarter. Wolff Financial Management LLC’s holdings in Pfizer were worth $1,195,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Exchange Traded Concepts LLC lifted its holdings in Pfizer by 10.2% during the 4th quarter. Exchange Traded Concepts LLC now owns 76,250 shares of the biopharmaceutical company’s stock worth $2,023,000 after buying an additional 7,072 shares during the last quarter. CX Institutional lifted its stake in Pfizer by 9.1% during the fourth quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company’s stock worth $1,337,000 after purchasing an additional 4,183 shares during the last quarter. Sound Income Strategies LLC increased its stake in Pfizer by 10.0% in the fourth quarter. Sound Income Strategies LLC now owns 764,822 shares of the biopharmaceutical company’s stock valued at $20,291,000 after purchasing an additional 69,416 shares during the last quarter. LexAurum Advisors LLC raised its holdings in Pfizer by 5.0% during the fourth quarter. LexAurum Advisors LLC now owns 28,112 shares of the biopharmaceutical company’s stock worth $746,000 after purchasing an additional 1,326 shares in the last quarter. Finally, Neumann Capital Management LLC boosted its holdings in shares of Pfizer by 50.6% in the 4th quarter. Neumann Capital Management LLC now owns 22,588 shares of the biopharmaceutical company’s stock valued at $599,000 after buying an additional 7,587 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PFE shares. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim decreased their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Stock Down 1.3 %

Pfizer stock opened at $26.10 on Friday. The stock’s 50 day moving average price is $26.08 and its 200 day moving average price is $27.95. The company has a market cap of $147.89 billion, a PE ratio of 35.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.